Clinical and economic outcomes of a prospective antimicrobial stewardship program (Q38035270)

27 August 2017

Clinical and economic outcomes of a prospective antimicrobial stewardship program (English)

1 reference

27 August 2017

Michael A Nowak

1

1 reference

27 August 2017

Robert E Nelson

2

1 reference

27 August 2017

Jesse L Breidenbach

3

1 reference

27 August 2017

Paul A Thompson

4

1 reference

27 August 2017

Paul J Carson

5

1 reference

27 August 2017

1 September 2012

1 reference

American Journal of Health-System Pharmacy

27 August 2017

1 reference

27 August 2017

69

1 reference

27 August 2017

17

1 reference

27 August 2017

1500-1508

1 reference

Estimating health care-associated infections and deaths in U.S. hospitals, 2002

27 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

A compendium of strategies to prevent healthcare-associated infections in acute care hospitals

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Overview of nosocomial infections caused by gram-negative bacilli

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Increased mortality associated with a clonal outbreak of ceftazidime-resistant Klebsiella pneumoniae: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Effect of Nosocomial Vancomycin-Resistant Enterococcal Bacteremia on Mortality, Length of Stay, and Costs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Novel classes of antibiotics or more of the same?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

The zeitgeist of resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Unnecessary use of fluoroquinolone antibiotics in hospitalized patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Practices to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Society for Healthcare Epidemiology of America/Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Controlling antimicrobial resistance in the hospital

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

ASHP statement on the pharmacist's role in antimicrobial stewardship and infection prevention and control

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

The value of infectious diseases specialists: non-patient care activities

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Impact of antimicrobial stewardship in critical care: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Antimicrobial stewardship programs as a means to optimize antimicrobial use. Insights from the Society of Infectious Diseases Pharmacists

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Antimicrobial stewardship programs: interventions and associated outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Impact of a hospital-based antimicrobial management program on clinical and economic outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Outcomes of an antimicrobial control program in a teaching hospital.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Favorable Impact of a Multidisciplinary Antibiotic Management Program Conducted During 7 Years

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Effectiveness of education and an antibiotic-control program in a tertiary care hospital in Thailand

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Antibiotic resistance--squeezing the balloon?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

“Collateral Damage” from Cephalosporin or Quinolone Antibiotic Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

Antimicrobial-associated risk factors for Clostridium difficile infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110603

31 March 2020

Identifiers

DOI

10.2146/AJHP110603

1 reference

27 August 2017

1 reference